First quarter report Q1-2023

• Study 0205 is progressing, with last patient expected in Q3
• Protocol finalized for study 0202, ready for submission in Q2
• Good progress with the commercialization strategy

“During the first quarter of 2023 focus was on ensuring progress in our clinical activities. Having implemented actions to improve recruitment levels into our pivotal 0205 study we are now confident that recruitment will be finalized during Q3 with top-line results following shortly after. We also finalized the protocol of our 0202-safety study which we expect to submit to authorities for approval during the second quarter of this year. Additionally, we continued to work on our commercialisation strategy in both the EU and US for CT001 and look forward to moving our plans forward in this area in the coming time” says Jes Trygved, CEO